Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Can Realty Income's Broad Reach Shield It and Drive Superior Returns?
Can Realty Income's Broad Reach Shield It and Drive Superior Returns?

Realty Income’s O ability to pay monthly dividends for 667 straight months is closely tied to how its portfolio is structured. The REIT owns more than 15,500 properties leased to more than 1,600

Pre-Markets in the Green After Trump's Comments at Davos
Pre-Markets in the Green After Trump's Comments at Davos

President Trump has arrived in Davos, Switzerland this morning, and presently at the podium for the annual World Economic Forum. This is, quite succinctly, the main even of this year’s forum — with

SMCI vs. META: Which AI Infrastructure Stock Has an Edge Now?
SMCI vs. META: Which AI Infrastructure Stock Has an Edge Now?

Super Micro Computer SMCI and Meta Platforms META are two prominent AI enablers, playing slightly different roles in the AI infrastructure supply chain. While SMCI positions itself as the supplier

GM vs. RACE: Which Auto-Manufacturer Stock Is the Better Buy Now?: https://staticx-tuner.zacks.com/images/articles/main/57/141355.webp
GM vs. RACE: Which Auto-Manufacturer Stock Is the Better Buy Now?

General Motors Company GM and Ferrari N.V. RACE are popular names in the automobile industry. While General Motors, along with its strategic partners, produces, sells and services passenger cars

Prologis Q4 FFO Meets Estimates, Rental Revenues Rise Y/Y
Prologis Q4 FFO Meets Estimates, Rental Revenues Rise Y/Y

Prologis, Inc. PLD reported fourth-quarter 2025 core funds from operations (FFO) per share of $1.44, meeting the Zacks Consensus Estimate. This compares unfavorably with the year-ago quarter’s

PRGS Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Shares Up
PRGS Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Shares Up

Progress Software PRGS reported fourth-quarter fiscal 2025 non-GAAP earnings of $1.23 per share, which beat the Zacks Consensus Estimate by 20.59% and increased 14.9% year over year.  Non-GAAP

NVTS vs. ADI: Which Semiconductor Stock Should You Buy Right Now?
NVTS vs. ADI: Which Semiconductor Stock Should You Buy Right Now?

Navitas Semiconductor NVTS and Analog Devices ADI are two key players operating in the semiconductor industry. They benefit from the growing demand for data centers, artificial intelligence (AI)

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

Capricor Therapeutics CAPR recently provided a regulatory update on its Biologics License Application (BLA) for Deramiocel, following recent interactions with the FDA. After reviewing topline data

ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission

Shares of ImmunityBio IBRX surged 17.4% after it announced a recent face-to-face meeting with senior FDA officials to align on the regulatory path forward for Anktiva in an additional indication

Notes on President Trump's Davos Speech: https://staticx-tuner.zacks.com/images/articles/main/84/143058.webp
Notes on President Trump's Davos Speech

Wednesday, January 21st, 2026President Trump has arrived in Davos, Switzerland this morning, and presently at the podium for the annual World Economic Forum. This is, quite succinctly, the main even

Riot Platforms: A $311M AMD Deal Changes the HPC Game: https://www.marketbeat.com/logos/articles/med_20260120120454_riot-platforms-a-311m-amd-deal-changes-the-hpc-gam.png
Riot Platforms: A $311M AMD Deal Changes the HPC Game

In mid-January, the financial markets witnessed a notable anomaly. While Bitcoin's ($BTC) price faced significant downward pressure, dropping toward $91,000 due to rising geopolitical tensions

Can Vertiv's International Expansion Drive More Upside in the Stock?
Can Vertiv's International Expansion Drive More Upside in the Stock?

Vertiv VRT is benefiting from strong international demand for data center infrastructure, driven by the global acceleration of digital transformation and AI adoption. The company reported a robust

Can B&G Foods' Margin Improvement Hold Amid Soft Demand?
Can B&G Foods' Margin Improvement Hold Amid Soft Demand?

B&G Foods, Inc.’s BGS third-quarter fiscal 2025 results reflect a difficult operating backdrop. Net sales declined 4.7% year over year to $439.3 million, while base business net sales, excluding

FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate

Eli Lilly and Company LLY announced that the FDA has granted a Breakthrough Therapy designation to its novel folate receptor alpha (FRα) antibody-drug conjugate (ADC), sofetabart mipitecan

SIFCO Plunges 14.3% in the Past Three Months: How to Play the Stock?
SIFCO Plunges 14.3% in the Past Three Months: How to Play the Stock?

SIFCO Industries, Inc.'s SIF investors have been experiencing some short-term losses from the stock of late. Shares of the Cleveland, OH-based manufacturer of forgings, sub-assemblies and machined

J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales

Johnson & Johnson’s JNJ fourth-quarter 2025 earnings came in at $2.46 per share, which beat the Zacks Consensus Estimate of $2.43. Earnings rose 20.6% from the year-ago period.

Adjusted earnings

Precious Metal ETF (DBP) Hits New 52-Week High
Precious Metal ETF (DBP) Hits New 52-Week High

Invesco DB Precious Metals ETF DBP is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and has moved up 88.86% from its 52-week low price of $62.84 per share.

GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics RAPT for an estimated aggregate equity value of $2.2 billion.

The

Reasons Why You Should Retain Fiserv Stock in Your Portfolio
Reasons Why You Should Retain Fiserv Stock in Your Portfolio

Fiserv, Inc.’s FISV growth is fueled by the rising adoption of Software-as-a-Service (SaaS) and payment solutions by business houses. Its new acquisitions and AI innovations aid it in gaining access

HWC Q4 Earnings Beat Estimates on Fee Income & NII, Shares Dip
HWC Q4 Earnings Beat Estimates on Fee Income & NII, Shares Dip

Hancock Whitney Corp.’s HWC fourth-quarter 2025 earnings per share of $1.49 beat the Zacks Consensus Estimate by a penny. Further, the bottom line rose 6.4% from the prior year quarter.Results

Are Options Traders Betting on a Big Move in Caleres Stock?
Are Options Traders Betting on a Big Move in Caleres Stock?

Investors in Caleres, Inc. CAL need to pay close attention to the stock based on moves in the options market lately. That is because the Feb. 20, 2026 $30 Call had some of the highest implied

Will Lower Active Accounts Impact Synchrony's Q4 Earnings Potential?
Will Lower Active Accounts Impact Synchrony's Q4 Earnings Potential?

Consumer financial services company, Synchrony Financial SYF, is set to report fourth-quarter 2025 results on Jan. 27, before the opening bell. The Zacks Consensus Estimate for the to-be-reported

Can PANW's Secure Browser Adoption Support Long-Term SASE Growth?
Can PANW's Secure Browser Adoption Support Long-Term SASE Growth?

Palo Alto Networks PANW is seeing strong growth in its Secured Access Service Edge (SASE) business, and secure browsers are becoming a bigger part of that story. In the first quarter of fiscal 2026

Implied Volatility Surging for Aris Mining Stock Options
Implied Volatility Surging for Aris Mining Stock Options

Investors in Aris Mining Corporation ARMN need to pay close attention to the stock based on moves in the options market lately. That is because the March 20, 2026 $5 Call had some of the highest

NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies

Novo Nordisk NVO and Aspect Biosystems announced that they are advancing their partnership into a new phase focused on developing next-generation cellular medicines for diabetes.

The companies have